Navigation Links
More Men Taking Testosterone, But Risks Unclear
Date:6/3/2013

MONDAY, June 3 (HealthDay News) -- Those late-night ads telling aging men that "low T" may be the reason they've lost the spring in their step appear to be reaching their audience. Use of testosterone therapy has increased dramatically over the past decade, according to a new study.

But experts worry that too many men may be taking the supplements without understanding the potential risks.

Researchers at the University of Texas Medical Branch at Galveston pointed out that the development of new drugs, particularly topical gels, also likely played a role in this trend.

The study, published in the current issue of JAMA Internal Medicine, involved more than 10 million men aged 40 years and older. The researchers found use of testosterone therapy was three times higher in 2011 than it was in 2001. Over the course of the decade, testosterone therapy increased from 0.81 percent to 2.91 percent.

The investigators noted that 2.29 percent of men in their 40s and 3.75 percent of men in their 60s were taking some form of testosterone therapy by 2011.

While sales may be booming, the risks involved with supplements of the powerful male hormone remain uncertain. One study presented last month at the annual meeting of the American Urological Association suggests that use of testosterone might be an underappreciated cause of male infertility.

The study, from the University of Alabama, found that sperm production bounced back to healthier levels when some men being treated at fertility clinics stopped using testosterone supplements.

Another study published at the same meeting found that many online vendors of testosterone supplements accentuate supposed benefits from the drug, but minimize the risk.

The study, which looked at 70 websites from companies across the United States, found that just 27 percent of the online vendors described potential side effects, which experts say can include liver problems, male breast growth, increased male pattern baldness, possible harm to prostate health, raised risks for blood clots, congestive heart failure and a worsening of urinary symptoms.

One expert added that, due to these risks, men should be cautious before succumbing to "low T" advertisements. According to Dr. John Amory, professor of medicine at the University of Washington in Seattle, the supplements -- which can cost between $75 to $300 per month -- are currently "being oversold to patients."

In the new study, hypogonadism -- a condition that affects a man's ability to produce normal levels of testosterone -- was diagnosed in about half of the men treated with testosterone therapy, the study indicated.

However, about one-quarter of the men given the hormonal treatment did not have their testosterone levels checked first. Of the remaining 75 percent of men who did have their hormone levels tested, it remains unclear what percentage had low testosterone levels.

"This trend has been driven, in large part, by direct-to-consumer marketing campaigns that have targeted middle-aged men and the expansion of clinics specializing in the treatment of low testosterone or 'low-T centers,'" the lead author of the study, Dr. Jacques Baillargeon, an associate professor in preventive medicine and community health at the University of Texas Medical Branch, said in a university news release.

More information

The U.S. National Library of Medicine has more about testosterone.

-- Mary Elizabeth Dallas

SOURCE: University of Texas Medical Branch at Galveston, news release, June 3, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
2. Seniors Stop Taking Heart Drugs In Medicare Donut Hole
3. Taking Away Car Keys Can Be Tough for Older Drivers
4. Taking Anti-HIV Meds Prior to Exposure May Help Prevent Infection
5. Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo
6. Young Men Taking HIV Meds May Be at Risk for Bone Loss
7. Taking the fate of stem cells in hand: RUB researchers generate immature nerve cells
8. Taking tissue regeneration beyond the state-of-the-art
9. Taking nothing at face value
10. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
11. More Kids Taking Antipsychotics for ADHD: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Men Taking Testosterone, But Risks Unclear
(Date:3/23/2017)... Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” ... or whose acts have had a significant impact on the careers of all others involved. ... with NRB Inc. was inducted into the MBI’s Hall of Fame. The induction took ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... serving the families and businesses of the Norwalk and Vermillion areas, celebrates ... Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer ...
(Date:3/23/2017)... ... 2017 , ... Benefits delivery trailblazer, Hodges-Mace, LLC, ... benefits dashboard solving one of the top frustrations in employee benefits – how ... time, employees can access up-to-date information and account balances for all of their ...
(Date:3/23/2017)... Angeles, CA (PRWEB) , ... March 23, 2017 ... ... A funding investment in Los Angeles based healthcare technology company California Healthcom Group ... portfolio into the US, and healthcare arena. With headquarters in California, CHG is ...
(Date:3/23/2017)... ... 23, 2017 , ... The TouchPoint Solution, home of Buzzies *, is ... anxiety. , “Buzzies change the way we interact with stress and live our ... its launch date in December 2016, The TouchPoint Solution has sold more than $750,000 ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017  The U.S. Food ... (avelumab) for the treatment of adults and pediatric patients ... (MCC), including those who have not received prior chemotherapy. ... a rare, aggressive form of skin cancer. ... cancers, patients with a rare form called Merkel cell ...
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 /PRNewswire/ ... "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company developing ... announced that data from its successful Phase 2a study ... treatment for localized prostate cancer, will be presented as ... nd Annual European Association of Urology in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... offering. ... global oxygen therapy devices market to grow at a CAGR of ... Oxygen Therapy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Medicine Technology: